Anzeige
Mehr »
Freitag, 18.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QR0E | ISIN: US2075231017 | Ticker-Symbol:
NASDAQ
17.07.25 | 21:57
1,800 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CONNECT BIOPHARMA HOLDINGS LTD ADR Chart 1 Jahr
5-Tage-Chart
CONNECT BIOPHARMA HOLDINGS LTD ADR 5-Tage-Chart

Aktuelle News zur CONNECT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoConnect Biopharma Regains Nasdaq Compliance On Minimum Bid Price259BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company focused on inflammatory disease treatments, announced that it has regained compliance...
► Artikel lesen
DoConnect Biopharma regains Nasdaq compliance with $1 minimum bid price3
DoConnect Biopharma Holdings Limited: Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement90SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming...
► Artikel lesen
DoConnect Biopharma Holdings Ltd - 8-K, Current Report1
09.07.Connect Biopharma's partner submits new drug application in China2
09.07.Connect Biopharma: Partner reicht Zulassungsantrag für Rademikibart in China ein3
09.07.Connect Biopharma Holdings Limited: Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China1
09.07.Connect Biopharma Holdings Ltd - 8-K, Current Report1
CONNECT BIOPHARMA Aktie jetzt für 0€ handeln
13.06.Connect Biopharma reports positive data for asthma treatment2
13.06.Connect Biopharma meldet positive Daten für Asthma-Behandlung3
13.06.Connect Biopharma Holdings Limited: Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress3
10.06.Connect Biopharma files $300M mixed securities shelf2
10.06.Connect Biopharma Holdings Ltd - S-8, Securities to be offered to employees in employee benefit plans1
03.06.Connect Biopharma Holdings Limited: Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress1
20.05.Connect Biopharma Announces Significant Findings Regarding Rademikibart312BEIJING (dpa-AFX) - Connect Biopharma Holdings Limited (CNTB), Tuesday announced clinical and preclinical data regarding rademikibart for the treatment of patients with asthma or COPD experiencing...
► Artikel lesen
15.05.Connect Biopharma Posts Wider Loss In Q1279BEIJING (dpa-AFX) - Connect Biopharma Holdings (CNTB) posted a net loss of $10.3 million, or $0.19 per share, for the three months ended March 31, 2025, compared with a net loss of $8.7 million...
► Artikel lesen
15.05.Connect Biopharma GAAP EPS of -$0.19 beats by $0.073
15.05.Connect Biopharma Holdings Ltd - 10-Q, Quarterly Report3
14.05.Connect Biopharma Holdings Limited: Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD309- Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 - SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect...
► Artikel lesen
13.05.Connect Biopharma begins Phase 2 asthma study2
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1